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ABSTRACT Our goal is to develop a pediatric combination vaccine to protect the
vulnerable infant population against human immunodeficiency virus type 1 (HIV-1)
and tuberculosis (TB) infections. The vaccine consists of an auxotroph Mycobacterium
tuberculosis strain that coexpresses HIV antigens. Utilizing an infant rhesus macaque
model, we have previously shown that this attenuated M. tuberculosis (AMtb)-simian
immunodeficiency virus (SIV) vaccine is immunogenic, and although the vaccine did
not prevent oral SIV infection, a subset of vaccinated animals was able to partially
control virus replication. However, unexpectedly, vaccinated infants required fewer
SIV exposures to become infected compared to naive controls. Considering that the
current TB vaccine, Mycobacterium bovis bacillus Calmette-Guérin (BCG), can induce
potent innate immune responses and confer pathogen-unspecific trained immunity,
we hypothesized that an imbalance between enhanced myeloid cell function and
immune activation might have influenced the outcome of oral SIV challenge in
AMtb-SIV-vaccinated infants. To address this question, we used archived samples
from unchallenged animals from our previous AMtb-SIV vaccine studies and vacci-
nated additional infant macaques with BCG or AMtb only. Our results show that vac-
cinated infants, regardless of vaccine strain or regimen, had enhanced myeloid cell
responses. However, CD4 T cells were concurrently activated, and the persistence
of these activated target cells in oral and/or gastrointestinal tissues may have facili-
tated oral SIV infection. Immune activation was more pronounced in BCG-vaccinated
infant macaques than in AMtb-vaccinated infant macaques, indicating a role for vac-
cine attenuation. These findings underline the importance of understanding the in-
terplay of vaccine-induced immunity and immune activation and its effect on HIV
acquisition risk and outcome in infants.
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Human immunodeficiency virus (HIV) and tuberculosis (TB) infections remain highlyprevalent in many parts of the world and often show substantial geographical
overlap. Infants represent one of the populations most vulnerable to both diseases. An
HIV vaccine is not yet available, and although a vaccine to prevent TB infection, the live
attenuated Mycobacterium bovis bacillus Calmette-Guérin (BCG) vaccine, is routinely
administered to 80% of neonates globally and is effective at preventing the most
severe complications of TB, BCG efficacy wanes with age (1–3). In HIV-infected infants
and infants at risk for HIV, the BCG vaccine is contraindicated due to the potential of
inducing disseminated BCG disease (4). Thus, both a new TB vaccine and a pediatric HIV
vaccine are urgently needed to reduce infant mortality and morbidity in areas of high
HIV and TB prevalence. Toward this goal, we aimed to develop a pediatric combination
HIV-TB vaccine that could protect infants against HIV and TB infections. Our vaccine was
intentionally designed to retain the immunogenicity of BCG but was more attenuated
to exhibit an improved safety profile, while expressing HIV antigens to induce both
HIV-specific and TB-specific immune responses. Further, we opted to utilize an atten-
uated human-adapted Mycobacterium tuberculosis for improved immune memory,
rather than further edit the M. bovis backbone of BCG.
Our pediatric TB-HIV combination vaccine is based on an auxotroph mutant of
Mycobacterium tuberculosis that has deletions in the panCD, leuCD, and secA2 loci that
render this attenuated M. tuberculosis (AMtb) strain mc26208 replication incompetent
(5–7). In fact, because these bacteria are unable to synthesize essential nutrients
(panthothenate and leucine), replication in unsupplemented conditions, such as a
mammalian host, can occur only temporarily until the cell reserves are depleted. In
contrast, BCG does not harbor auxotroph mutations and can replicate freely until
thwarted by the host immune system. Using experimental simian immunodeficiency
virus (SIV) infection of infant rhesus macaques, an animal model of pediatric HIV
infection, we have previously demonstrated that this AMtb vaccine, in contrast to BCG,
does not cause mycobacterial dissemination or TB tissue pathology (8). Further mod-
ification of the mc26208 vaccine strain to coexpress SIVgag (mc26435) or SIVenv
(mc26439) rendered this vaccine capable of inducing both TB- and SIV-specific T cell
and antibody responses in infant macaques (9, 10). Although these vaccine-induced
SIV-specific immune responses were not sufficient to prevent oral SIV acquisition, a
subset of vaccinated infant macaques with higher-avidity plasma SIV Env-specific IgG
antibodies and SIV Env-specific mucosal IgA antibodies showed better control of SIV
replication upon infection (9). At the same time, unexpectedly, the group of vaccinated
infant macaques had a twofold-higher SIV infection risk per exposure compared to
unvaccinated infants (9). Despite not being statistically significant, the difference in the
per exposure risk of SIV infection was reminiscent of increased CD4 T cell activation,
and thereby a potentially increased risk of HIV infection, seen in South African infants
after BCG vaccination (11, 12).
In human neonates, a single immunization with BCG at birth has been shown to be
highly immunogenic despite the infant’s reduced ability to mount potent T helper 1
(Th1) responses. Further, the introduction of the BCG vaccine has been associated with
a significant drop in overall childhood mortality. In addition to protection against TB,
inherent adjuvant properties of BCG can improve immunological responses to other
neonatal vaccines (13, 14). Only recently have we begun to understand the mecha-
nism(s) by which BCG can exert these beneficial effects. Studies in human adults have
shown that BCG vaccination induces epigenetic modifications in monocytes that can
persist for several months, resulting in improved functional capacity and higher re-
sponses to both M. tuberculosis and unrelated antigens (15). This phenomenon, which
has been characterized as an aspect of “trained immunity,” was not restricted to
monocytes and macrophages that are the target cells for mycobacteria but was also
extended to T cells (16). Therefore, it has been proposed that novel TB vaccine
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candidates should aim to preserve these unique features of BCG. In fact, among the
new TB vaccine candidates under development, several are based on additional
attenuations of M. bovis within the existing BCG vaccine or on attenuated M. tubercu-
losis strains similar to the auxotroph AMtb vaccines used here (17–21). Recombinant
BCG strains expressing HIV antigens are also in development as potential HIV vaccines
and have been tested in mice (22–24) and in adult (25–29) and neonatal (30) macaques.
Considering the high risk of HIV and TB infection in infants, especially in sub-Saharan
Africa, we deemed it important to understand how novel TB vaccines or combination
HIV-TB vaccines might impact HIV acquisition.
In a first attempt to better define the beneficial effects of mycobacterial vaccines
and to weigh them against potentially negative outcomes on infant HIV infection risk,
we report here studies conducted on archived tissue samples from animals immunized
with the AMtb-SIV prime/modified vaccinia Ankara (MVA)-SIV boost regimen that were
not challenged with SIV (10) or samples from animals included in our recent efficacy
studies that were collected prior to or at the time of the first SIV challenge (9). To
exclude any effects of the vaccine booster component or the SIV inserts on oral SIV
acquisition, we expanded upon those historical studies by vaccinating infant macaques
with AMtb vaccines only (AMtb-SIV prime plus a homologous boost) or animals primed
only with AMtb-SIV, the AMtb strain without SIV cassettes, or the human infant regimen
of BCG. Specifically, the current study examined the potential of our AMtb vaccine to
increase functional responses of infant monocytes/macrophages and whether en-
hanced myeloid cell function was associated with immune activation that could
potentially predispose infants to SIV infection.
RESULTS
Increased functional responses in myeloid cell population of AMtb-vaccinated
infant macaques. In human adults, the persistence of heightened monocyte function
has been described as a hallmark of BCG-induced trained immunity (15, 31, 32). To
determine whether our AMtb vaccine mc26435 (expressing SIVgag) could also enhance
monocyte responses and whether it could do so in the pediatric setting, we utilized
archived peripheral blood mononuclear cell (PBMC) and tissue samples from SIV-
uninfected infant macaques that were vaccinated with strain mc26435 at birth, boosted
with MVA-SIV at 3 and 6 weeks of age, and monitored for 16 to 18 weeks to determine
vaccine-induced SIV- and TB-specific immune responses in blood and tissues (10). As
mycobacteria infect not only monocytes/macrophages but also dendritic cells (DC), we
tested both monocytes/macrophages and myeloid DC (mDC) for their ability to pro-
duce cytokines in response to Toll-like receptor (TLR) ligation. Although mycobacteria
are not known to signal through Toll-like receptor 7 (TLR7) or TLR8, we chose the
TLR7/8 agonist R848 because monocytes/macrophages and myeloid dendritic cells
from infants show reduced function compared to those from adults, and R848 has been
demonstrated to potently activate infant cell populations (33, 34). At 16 to 18 weeks
after vaccination, in vitro R848 stimulation of PBMC resulted in higher frequencies of
interleukin 12 (IL-12)-producing monocytes/macrophages (Fig. 1A) and mDC (Fig. 1B) in
vaccinated animals than in naive control animals, but these differences were not
statistically significant. Peripheral blood monocytes/macrophages of AMtb-vaccinated
infant macaques did, however, express increased levels of the activation markers CCR5
(chemokine [C-C motif] receptor 5) and CD69 compared to naive controls (Fig. 1C). In
contrast to PBMC, tissue analyses revealed clear differences in the functional capacity
of myeloid cell populations from AMtb-vaccinated and unvaccinated infant macaques.
It is particularly noteworthy that greater frequencies of IL-12- or tumor necrosis factor
alpha (TNF-)-producing monocytes/macrophages (Fig. 1D) and mDC (Fig. 1E) were
observed in the tonsils and submandibular lymph nodes (LN) of AMtb-vaccinated
animals compared to naive controls. These results indicated that a single oral admin-
istration of an AMtb vaccine during the first week of life could enhance the function of
infant monocytes/macrophages and mDC and that these responses persisted for at
least 16 to 18 weeks in blood and tissues of infant macaques. As oral and intestinal
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tissues are presumed sites of entry and early SIV replication after oral exposure and our
goal is to develop a pediatric HIV-TB combination vaccine, we deemed it important to
test whether the AMtb vaccination had also resulted in CD4 T cell activation.
Prolonged CD4 T cell activation after AMtb vaccination of infant macaques.
Indeed, 16 to 18 weeks after vaccination with AMtb, the frequencies of CD4 CCR5 T
cells were significantly higher in PBMC, retropharyngeal LN, and colons of AMtb-
vaccinated animals than in naive controls (Fig. 2). In addition, frequencies of Ki-67,
PD-1, and CD69 CD4 T cells were generally higher in retropharyngeal LN and colon
cell suspensions of cells from AMtb-vaccinated infants than in those from naive controls
FIG 1 Increased functional responsiveness of monocytes/macrophages and mDC. (A and B) Frequencies of IL-12- or TNF--producing monocytes/macrophages
and mDC, respectively, in PBMC from naive controls and AMtb-vaccinated infant macaques at 16 to 18 weeks after vaccination. (C) Frequencies of CCR5 or
CD69 peripheral blood monocytes/macrophages from the same animals. (D and E) Frequencies of TNF-- or IL-12-producing monocytes/macrophages (D) and
mDC (E) from the axillary (Ax.), mesenteric (Mes.), and submandibular (Subm.) lymph nodes (LN) and tonsils of vaccinated infant animals after in vitro stimulation
with R848. Each symbol represents the value for an individual animal. The short horizontal bar in all graphs represents the median value for the group.
Statistically significant differences between the groups are listed as P values and were determined by exact Mann-Whitney test.
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(Fig. 2). Although only PBMC, retropharyngeal LN, and colons were available for this
retroactive analysis, these data further confirmed that the AMtb-induced immune
activation persisted for several weeks to months after vaccination and provided evi-
dence that SIV target cell frequencies at presumed sites of viral entry and/or early
replication were concurrently increased. These findings of persistent AMtb vaccine-
induced immune activation in myeloid cell and CD4 T cell populations in blood and
tissues reiterated the important question of whether vaccine-induced immune activa-
tion could enhance the risk for HIV/SIV infection, as suggested by the results of the STEP
HIV vaccine trial (35–37).
Study design to test the association between AMtb or BCG vaccines and oral
SIV challenge outcome. We recently reported that an AMtb-SIV prime/MVA-SIV boost
regimen did not protect infant macaques against oral SIV infection; furthermore,
vaccinated animals appeared to require fewer oral SIV exposures to become infected
compared to naive controls (9). The current study was designed to include additional
control groups to more conclusively determine whether mycobacterial vaccines would
predispose infant macaques to SIV infection. Vaccine-induced adaptive immune re-
sponses were previously reported (9, 10) and were not assessed in these cohorts. Here,
we tested whether mycobacterial vaccines could induce innate immune responses and
immune activation. As outlined in Fig. 3, control animals consisted of nine infant
macaques that received placebo (phosphate-buffered saline [PBS]) immunization
(group C2) and also included the six historical control animals (group C1) from our
previous study (9). Similar to the vaccinees in the former study (group D), infant
macaques in group E were immunized at birth with mc26435 and mc26439, but instead
of receiving heterologous MVA-SIV boosts, the animals received the same mc26435 and
mc26439 vaccines (homologous boost) at week 3 by the intradermal (i.d.) route, the
current route of BCG vaccination. To exclude other confounding factors, such as SIV
antigen expression by AMtb vaccines, group F infant macaques were vaccinated with
a single dose of mc26208, the parental vaccine strain of mc26435/mc26439 that does
not contain SIV expression cassettes. A group of single-dose BCG-vaccinated infants
was also included (group G) as a control for vaccine-induced enhanced myeloid cell
function and to determine whether any of the effects described here for experimental
AMtb vaccines may have translational potential for novel TB vaccine in human infants.
Weekly repeated low-dose oral SIVmac251 challenges were started at week 9 (Fig. 3).
On the basis of our observations of persistent immune activation in blood and tissues
at 16 to 18 weeks after AMtb vaccination of SIV-unexposed infant macaques, we asked
whether we could detect activated myeloid cell populations or increased numbers of
CCR5-positive CD4 T cells (preferred targets for SIV infection) at the time of challenge
(week 9).
Increased function of peripheral blood monocytes/macrophages and mDC of
infant macaques vaccinated with AMtb or BCG vaccine at the start of oral SIV
challenges. To address this question, we stimulated PBMC that were collected at the
time of the start of repeated low-dose oral SIV exposures (week 9) with R848. To
FIG 2 CD4 T cell activation in tissues at 16 to 18 weeks after AMtb vaccination. Percentages of CCR5-, Ki67-, PD-1-, and CD69-positive CD4 T cells were
measured by flow cytometric analysis in PBMC, retropharyngeal lymph nodes, and the colon at 16 to 18 weeks postvaccination. See the legend to Fig. 1.
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increase our sample size, we included a group of infant macaques that received a single
immunization with mc26435 at birth (group H [Fig. 3]); this group was not included in
the SIV challenge analysis, because these infants were challenged with a high dose of
SIVmac251. Indeed, the frequencies of IL-12-producing monocytes were significantly
higher in PBMC from AMtb- or BCG-vaccinated infant macaques than from naive control
animals, whereas TNF- responses were increased only in AMtb-vaccinated infants (Fig.
4A). Infant macaques vaccinated with AMtb or BCG also had significantly higher
frequencies of IL-12- or TNF--producing mDC than naive controls (Fig. 4A).
We next tested whether these enhanced functional responses of monocytes/mac-
rophages and mDC were associated with systemic immune activation. Week 9 plasma
samples were analyzed for a panel of cytokines and chemokines that included several
proinflammatory markers. However, none of the cytokines typically associated with
inflammation and immune activation, e.g., TNF-, IL-6, IL-1, and IL-8, were elevated in
vaccinated infant macaques. In fact, out of 37 cytokines, chemokines, and growth
factors tested, only macrophage chemoattractant 1 (MCP-1) and macrophage inflam-
matory protein 1 (MIP-1) were significantly increased in the plasma of vaccinated
FIG 3 SIV challenge study outline. The figure shows the times of immunization (indicated by black arrows), the time of oral
SIV exposures (red arrows), and lists the vaccine regimens for each of the groups. The number of animals per group is
indicated, and each group is assigned a colored symbol. The route of vaccine administration is given in parentheses as
follows: PO, per os; IM, intramuscular; ID, intradermal. *, animal groups have been described in reference 10; **, animal
groups have been described in reference 9.
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animals (Fig. 4B). Both of these cytokines represent markers of monocyte activation.
Therefore, we performed further testing for soluble CD14 (sCD14) and sCD163 that are
produced by activated monocytes. To account for the large variation in absolute levels
between animals and to focus our analysis on vaccination-related changes, we used the
ratio of plasma sCD14 and sCD163 levels at week 9 normalized to those at week 0 for
FIG 4 Vaccine-induced activation of myeloid cells at the time of SIV challenge. (A) Frequencies of IL-12- and TNF--producing monocytes/macrophages and
mDC in peripheral blood from naive controls, AMtb-vaccinated, and BCG-vaccinated infant macaques at week 9, the time when oral SIV challenges were
initiated. (B) Plasma levels of MCP-1 and MIP-1 were measured when the infants were 9 weeks old. The plasma levels of sCD14 and sCD163 are reported as
a ratio of the level at week 9 (start of SIV challenge) divided by the level at week 0 (time of immunization). Note that due to the small blood sample volume
available from infants, plasma samples were not available for all infants at all time points. Each symbol represents the value for an individual animal with
different vaccine groups being identified by their respective colored symbol (Ctrls, controls). Statistically significant differences between the groups are listed
as P values and were determined by exact Mann-Whitney test.
Trained Immunity and Immune Activation of TB Vaccines Clinical and Vaccine Immunology
January 2017 Volume 24 Issue 1 e00360-16 cvi.asm.org 7
each animal. Animals vaccinated with AMtb or BCG had a significant increase in sCD14
plasma levels, with the increase in sCD14 being significantly higher in BCG-vaccinated
compared to AMtb-vaccinated infant animals (Fig. 4B). Vaccination was not associated
with increased sCD163 plasma levels (Fig. 4B). Consistent with our conclusion that the
mycobacterial vaccine component(s), and not MVA boosting or SIV antigen expression,
was driving myeloid cell activation, we observed increased functional responses and
elevated plasma cytokine levels when we compared each of the AMtb vaccine groups
separately to the naive control animals at week 9 (see Fig. S1 in the supplemental
material).
To determine whether the elevated plasma cytokine levels were at least partially due
to myeloid cell activation, we tested whether changes in plasma cytokine levels were
correlated with functional measurements of myeloid cells at week 9. Indeed, the
frequencies of IL-12-producing peripheral blood monocytes/macrophages and mDC
were positively correlated with plasma MCP-1 levels (Fig. 5A), but not MIP-1 level (data
not shown). This correlation was maintained when we analyzed the relationship
between IL-12-positive (IL-12) monocytes/macrophages of BCG-vaccinated animals
and naive control animals to plasma MCP-1 (Fig. 5B), but it was not statistically
significant when we tested naive controls and AMtb-vaccinated infants (P  0.0940)
(data not shown). We also observed positive correlations between plasma sCD14 and
sCD163 week 9/week 0 ratios and week 9 IL-12monocyte/macrophage frequencies in
BCG-vaccinated infants, but not in AMtb-vaccinated infants (Fig. 5B).
Vaccine-induced CD4 T cell activation at the start of oral SIV challenges.
Analysis of longitudinal blood samples showed that all AMtb- and BCG-vaccinated
infant animals experienced an increase in CD4 CCR5 T cells after vaccination. However,
consistent with the changing ratio of naive to antigen-experienced CD4 T cells as part
of normal immune development, the frequencies of CCR5 CD4 T cells increased in
all groups between week 0 and week 9 (Fig. 6A). Thus, it was important to distinguish
between changes in peripheral blood immune cell populations that reflect normal
FIG 5 Correlation between in vitro myeloid cell responses and systemic immune activation. (A) Positive correlation between frequencies of IL-12-producing
monocytes/macrophages (left) or mDC (right) after in vitro R848 stimulation and plasma MCP-1 levels at week 9. (B) Correlation between IL-12-producing
monocytes/macrophages and MCP-1, sCD14, and sCD163 including only naive controls and BCG-vaccinated animals in the analysis. Correlations were
determined by Spearman rank test. Wk., week.
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FIG 6 PBMC CD4 T cell activation at week 9. (A) Frequencies of CCR5 CD4 T cells for individual animals in each group at week 0 (time of immunization)
and week 9 (start of SIV challenge); P values were determined by Wilcoxon signed-rank test. The right graph shows the ratio of CD4 CCR5 T cell frequencies
at week 9 over week 0. P values in this figure were calculated by exact Mann-Whitney test. (B) Between group comparisons in frequencies of CD4 T cells
(Continued on next page)
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postnatal immune development (38) and vaccine-induced immune activation. There-
fore, we report all changes in activated CD4 T cell frequencies as ratios of week 9
values compared to week 0 values for each animal. This analysis revealed that BCG-
vaccinated infants had significantly higher frequencies of CD4 CCR5 T cells than
naive controls at 9 weeks of age (Fig. 6A). Although CD4 CCR5 T cells were not
increased in AMtb-vaccinated infants, vaccine-induced CD4 T cell activation was
suggested by significantly higher frequencies of CD69 and PD-1 CD4 T cells
compared to the naive controls (Fig. 6B). BCG-vaccinated infants showed a significant
rise in Ki67, CD69, and in PD-1 CD4 T cells (Fig. 6B).
Immune activation of CD4 T cells was further substantiated by higher levels of
endogenous cytokines in ex vivo unstimulated CD4 T cells from vaccinated animals
compared to unvaccinated infant macaques (Fig. 6C). Compared to naive controls,
CD4 T cells from both AMtb- or BCG-vaccinated infants had significantly increased
levels of IL-2, gamma interferon (IFN-), and TNF- at week 9, while IL-17A levels were
increased only in the BCG-vaccinated infants (Fig. 6C). It should be pointed out that this
analysis was performed on ex vivo isolated cells without any stimulation and that the
measured frequencies of cytokine-producing CD4 T cells exceeded those of antigen-
specific (both SIV and TB) CD4 T cells (9, 10), and thus are consistent with immune
activation as opposed to memory responses. Furthermore, an analogous analysis of
PBMC samples collected from infant macaques vaccinated with a DNA-SIV prime/MVA-
SIV boost regimen did not reveal similar CD4 T cell activation (Fig. 6D). These results
were confirmed by the statistical significance of separate comparisons of individual
AMtb vaccine groups to naive control animals (Fig. S2), indicative of mycobacterial
vaccine-driven CD4 T cell activation.
These combined data show that early vaccination with highly replication-attenuated
auxotroph M. tuberculosis vaccine strains or with attenuated, but replication-competent
BCG, induced activation in myeloid cells and in CD4 T cells that was clearly evident at
9 weeks after vaccination, the time of the first oral SIV challenge. While we focused our
discussion of mycobacterial-vaccine-induced immune activation on myeloid cells and
CD4 T cells as the cell types most relevant to SIV acquisition, vaccine-induced immune
activation was also observed in CD8 T cells and in B cells (Fig. S3), underlining the
global nature of systemic immune perturbation, even months after mycobacterial
vaccination. Functional differences of CD8 T cells and B cells between naive controls
and AMtb- or BCG-vaccinated infants could not be further explored within the scope of
the current study.
Challenge outcome in AMtb- or BCG-vaccinated infant macaques using a
repeated low-dose oral SIV exposure model. Similar to our recent study (9), in
which unvaccinated infants had an SIV infection risk per exposure of 0.24, the SIV
infection risk per exposure for naive controls was 0.25 in the current study. Thus, 4
of 9 naive controls (44%) became infected after 1 SIV exposure, with 1 animal each
requiring 3, 4, 5, or 6 exposures, and 1 animal failing to become persistently
infected after 10 oral SIV exposures (not persistently infected [NPI]) (Fig. 7A). In
contrast, AMtb-vaccinated infants in groups E and F tended to become infected
after fewer SIV exposures, with 8 of 11 animals (73%) becoming infected after only
one or two exposures (Fig. 7B) and 1 group F animal requiring four exposures. As
one infant each in groups E and F remained uninfected after 10 SIV exposures, the
SIV infection risk per exposure (0.34) in infant macaques vaccinated with AMtb
vaccines was lower than in our previous study using the AMtb-SIV prime/MVA-SIV
FIG 6 Legend (Continued)
expressing Ki-67, CD69, or PD-1 from week 9 to week 0 (exact Mann-Whitney P values). (C) Percentages of IL-2-, IFN--, IL-17-, and TNF--producing CD4 T
cells in animals from each experimental group at week 9 (exact Mann-Whitney P values). (D) Percentages of CCR5-, Ki-67-, CD69-, PD-1-, and TNF--positive CD4
T cells at week 12 in infant macaques who received an oral DNA-SIV vaccine at weeks 0 and 3 and were vaccinated with MVA-SIV at weeks 6 and 9 by both
the intramuscular (i.m.) and sublingual route (DNA expressing SIVmac239 was encapsulated in cationic liposomes and administered at 3 mg/animal into the
mouth; MVA expressing SIV Gag, Pol, and Env was administered at 108 PFU by both the i.m. and sublingual route; K. De Paris, unpublished data). No statistically
significant differences were noted between week 0 (open triangles) and week 12 (black triangles) values by Wilcoxon signed-rank test.
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boost regimen (exposure risk of 0.5) (9). Similar to AMtb, five of seven BCG-
vaccinated infants (71%) became infected after a single oral SIV exposure, while one
animal required two exposures and one animal remained uninfected for an esti-
mated probability of infection per oral SIV exposure of 0.35 (Fig. 7C).
Given the overall similarity in challenge outcome between the previous (9) and
current studies, we combined the animals of both studies to assess the risk of SIV
infection. These results translated into a per exposure risk of SIV infection of 0.25 for
naive controls (groups A and C) and 0.34 for infant animals receiving any kind of AMtb
vaccine (groups D, E, and F). As one unvaccinated infant (group C), two AMtb-
vaccinated infants (groups D to F) and one BCG-vaccinated infant (group G) had to be
categorized as NPI, there was only a 1.4-fold increased risk of SIV infection per exposure
in vaccinated animals compared to naive control animals. Comparing the AMtb-
vaccinated animals (n  19) or the BCG-vaccinated animals (n  7) to the control
animals (n  15), we did not detect statistically significant differences in the number of
SIV exposures until infection (P  0.6 and P  0.8, respectively; Fig. 7D). Yet, descrip-
tively, after only two low-dose oral SIV exposures, 79% of AMtb-vaccinated and 88% of
BCG-vaccinated infants were infected compared to 47% of naive controls. Furthermore,
BCG-vaccinated animals (group G) exhibited significantly higher acute viremia (weeks
1 to 3 postinfection) than AMtb-vaccinated animals or naive controls (Fig. 7E), and they
tended to have higher viremia during the period after the acute phase of infection
(weeks 5 to 7 postinfection; Fig. 7F).
To exclude genetic factors associated with increased susceptibility or resistance to
SIV infection or with disease outcome, we determined the tripartite motif-containing
protein 5 (TRIM5) and major histocompatibility complex (MHC) class I genotypes of
SIV-challenged animals. The TRIM5 genotypes TFP/TFP and TFP/Cyp confer resistance
to SIV infection, while the genotypes Q/Q and Q/CypA are associated with increased
susceptibility to infection (39, 40). The MHC alleles Mamu A*01, B*08, and B*17 alleles
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FIG 7 Challenge outcome using a repeated low-dose oral SIV exposure model. (A) Plasma viremia of naive controls (group C2) after weekly low-dose oral
SIVmac251 exposures, starting at 9 weeks of age. (B) SIV challenge outcome for AMtb-vaccinated infants of group E (orange diamonds) and group F (empty
diamonds). (C) Challenge outcome of BCG-vaccinated infants. The horizontal axes in panels A to C show the age of the animals. (D) Inverted Kaplan-Meier
estimate for the probability of infection per cumulative low-dose SIV exposure for naive controls (groups C1 and C2), AMtb-vaccinated infants (groups B, D, E,
and F), or BCG-vaccinated infants (group G). The exact log rank test P value was not statistically significant. (E and F) Acute and post-acute viremia in naive
controls, AMtb-, or BCG-vaccinated infants. The P values were determined by exact Mann-Whitney test.
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have been associated with improved control of viral replication and better disease
outcome, whereas allele B*01 is associated with higher viremia (41–46). Genotypes
could not be evaluated prior to enrollment because animals were assigned to the
different groups within 3 days of birth. Animals that required more challenges or were
resistant to SIV infection showed no bias toward protective TRIM5 alleles or MHC class
I alleles, as calculated in the susceptibility score (Table 1). Conversely, animals infected
after fewer SIV exposures were not more likely to express alleles associated with greater
susceptibility to infection or with reduced control of viremia. Although none of the
animals in groups D and E expressed the protectiveMamu A*01 allele, “MHC protection”
refers to the ability to control virus replication better in infected animals; there are no
reports, to our knowledge, that conclusively show that the Mamu A*01 genotype
protects against SIV infection. Similarly, TRIM5 alleles have not been associated with
resistance to infection with the pathogenic strains SIVmac239 or SIVmac251 (47). Therefore,
TABLE 1MHC class I and TRIM5 genotypes
Group and
animal no. Sexa
MHC class I
typeb
TRIM5
genotypec
Susceptibility
scored
No. of SIVmac251
exposures
Age (wk) at
euthanasia
Group Ce
44586 F B*01, B*17 Q/CypA 1 4 16
44618 M B*01 TFP/TFP 0 3 16
44684 F A*02, B*08 TFP/TFP 2 NPIf 20
44694 F B*01 TFP/TFP 0 1 15
44696 M B*17, B*29 TFP/TFP 2 1 15
44698 F B*01, B*08 TFP/TFP 1 1 14
44718 M A*01 TFP/Q 1 6 20
44739 M Negativeg TFP/Q 0 5 20
44746 F A*01 TFP/Q 1 1 19
Group Dh
Group E
42903 F Negative TFP/Q 0 1 21
42918 M A*01, B*01 TFP/TFP 1 NPI 34
42925 F Negative TFP/Q 0 1 21
42943 M A*01 TFP/Q 1 2 21
42947 F A*01 TFP/CypA 2 1 20
42950 M Negative TFP/Q 0 1 20
Group F
44146 F B*17, B*29 TFP/Q 1 1 17
44151 F Negative TFP/Q 0 2 17
44155 F B*01, B*17, B*29 TFP/CypA 1 1 17
44159 F A*11, B*17, B*29 Q/Q 0 4 17
44160 F Negative TFP/Q 0 NPI 41
Group Gi
44165 M A*02, B*01 TFP/TFP 0 NPI 41
44166 M B*01 TFP/TFP 0 1 16
44169 M B*01 TFP/TFP 0 1 16
44176 M Negative TFP/TFP 1 2 18
44180 F A*08 Q/Q 1 1 18
44186 F A*02 TFP/TFP 1 1 17
44195 M A*08 TFP/Q 0 1 17
aF, female; M, male.
bThe Mamu A*01, B*08, and B*17 alleles have been associated with better disease outcome, whereas allele B*01 is associated with higher viremia.
cThe TRIM5 genotypes TFP/TFP and TFP/CypA confer resistance to SIV, while the genotypes Q/Q and Q/CypA are associated with increased susceptibility to infection.
dProtective class I alleles and resistant TRIM5 alleles (A*01, B*08, TFP/TFP, and TFP/CypA) were assigned a value of 1. Genotypes associated with increased
susceptibility or disease outcome received a score of 1. All other alleles were assigned a score of 0. The susceptibility score represents the sum of all scores for an
individual animal (e.g., animal 42376 has MHC 1  0  1  0 and TRIM5 of 0 for a score of 2).
eIn addition, group C includes the six naive control animals (group C1) described by Jensen et al. (9).
fNPI, not persistently infected.
gNegative, not positive for any of the Mamu class I alleles tested (A*01, A*02, A*08, A*11, B*01, B*03, B*04, B*08, B*17, and B*29).
hMHC class I and TRIM5 genotypes are published in the study by Jensen et al. (9).
iNote that group H is not included in this table, because animals received a high-dose SIV challenge and were used for week 9 immune activation measurements, but
not for SIV risk calculations. Animals in groups A and B were not exposed to SIV.
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we concluded that the genotype of each animal was not a principal cause of enhanced
SIVmac251 acquisition in vaccinated animals.
Collectively, although statistically not significant, the SIV challenge results suggested
that infant macaques vaccinated with AMtb vaccines or BCG showed a trend toward
enhanced SIV acquisition compared to vaccine-naive controls.
Persistence of vaccine-induced immune activation post-SIV challenge. Al-
though BCG-vaccinated animals had higher viremia after infection, CD4 T cell loss did
not differ significantly between these animals, naive controls, and AMtb-vaccinated
infant animals (data not shown). Histological analysis also revealed no differences in the
integrity of the mucosal epithelium between the naive controls and AMtb- or BCG-
vaccinated groups (data not shown). It is also important to note that mycobacteria
could not be recovered from the lung or tracheobronchial lymph nodes of any of the
animals at the time of euthanasia. Despite similar clinical outcome, differences in
activation of myeloid cells and CD4 T cells between naive controls and AMtb- or
BCG-vaccinated infants were still apparent post-SIV infection. BCG-vaccinated animals
had higher frequencies of CCR5 monocytes/macrophages in the submandibular
lymph nodes and in bronchoalveolar lavage (BAL) fluid than naive control infants did
(Fig. 8A). HIV and SIV infections have been associated with increases in CD14 CD16
cells (48, 49), and while the frequency of activated CD14 CD16 peripheral blood
monocytes in naive controls increased from a median of 4.2% at week 9 to 24.5% after
SIV infection (Fig. 8B), even higher frequencies of this cell population were observed in
blood and tissues of AMtb- and BCG-vaccinated infants. At the time of euthanasia,
BCG-vaccinated animals also had higher frequencies of activated CD4 T cells in
lymphoid tissues than naive controls did (Fig. 9), but differences were not consistently
observed in mucosal tissues. In contrast, tissue CD4 T cell activation generally did not
FIG 8 Myeloid cell activation in blood and tissue samples from vaccinated and SIV-infected infants. (A) Frequencies of CCR5 CD14 cells in lymphoid and
mucosal tissues at the time of euthanasia (Table 1) for animals in group C, F, and G. (B) Frequencies of CD16 CD14 cells in PBMC and tissues. The P values
were determined by Wilcoxon signed-rank test for CD16 CD14 cells in PBMC from naive controls at week 9 compared to week 16 and by exact Mann-Whitney
test in all other samples.
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differ significantly between AMtb-vaccinated infants and naive controls, except for
higher frequencies of CCR5 and Ki-67 CD4 T cells in the ilea of AMtb-vaccinated
infants (Fig. 9). Similarly, the activation of CD8 T cells and B cells was more pro-
nounced in BCG-vaccinated animals (Fig. S4 and S5).
Differential immune activation of human myeloid cells by BCG and strain
mc26435 in vitro. Our data suggested that immune activation of myeloid cell popu-
lations might be more pronounced after BCG than AMtb vaccination, and thus, we
wanted to confirm this effect in human myeloid cells. This direct comparison was also
important because the AMtb and BCG vaccines were administered at different doses
and routes in the infant macaque studies, making a quantitative comparison of immune
responses between these two groups difficult. However, the main goal of our studies
was to determine whether enhanced myeloid cell function was induced by both
FIG 9 CD4 T cell activation in SIV-infected infant macaques. (A to C) Frequencies of CCR5-, Ki-67-, and PD-1-positive CD4
T cells in lymphoid and mucosal tissues from naive controls and AMtb- and BCG-vaccinated animals at the time of euthanasia.
The P values were determined by exact Mann-Whitney test.
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vaccine regimens, and thus likely mediated by mycobacteria. To assess for common
signaling properties, we first used the HEK-Blue human TLR reporter cell assay to
evaluate the TLR2, TLR4, or TLR8 signaling by M. tuberculosis-SIV vaccine strain
mc26435, BCG, and Mycobacterium smegmatis mc2155. The highest TLR2 signal was
observed after stimulation with M. smegmatis, which is thought to be the least
immunogenic of the mycobacteria tested (Fig. 10). However, in contrast to the other
strains, the replication of M. smegmatis is not attenuated, and the higher replication
rate may have resulted in stronger signaling. None of the mycobacterial strains induced
signaling via TLR4 or TLR8 in a 24-h time period.
We then incubated human PBMC with strain mc26435 or BCG and measured the
induction of activation markers and cytokines. Heat-killed mycobacteria (heat-killed M.
tuberculosis [HK-Mtb]) and R848 were included as controls; all responses were corrected
for baseline values in unstimulated cultures. Peripheral blood monocytes/macrophages,
but not mDC, stimulated with BCG showed higher induction of the costimulatory
molecules CD40, CD80, and CD86 than mc26435-stimulated cells did (Fig. 11). Consis-
tent with stronger myeloid cell activation, frequencies of IL-12- and TNF--producing
monocytes/macrophages and mDC were also higher after BCG stimulation than after
mc26435 stimulation (Fig. 12A), and these results were confirmed by increased proin-
FIG 10 Mycobacterium strains induce TLR2-mediated signaling. (A) Image of the reporter cell line culture plate after 15 h of incubation
and the plate template. Blue color is indicative of SEAP secretion and subsequent substrate hydrolysis in culture supernatants.M. smeg,
M. smegmatis. (B, left) Relative increase in NF-B induction by heat-killed M. tuberculosis (HK-Mtb), LPS, R848, or TNF- compared to
media in HEK reporter cell lines for TLR2, TLR4, or TLR8. (Right) Relative increase in TLR2-mediated NF-B activation induced by
mc26435, BCG, or M. smegmatis mc2155. The sample optical density (OD) readings were first corrected for background by subtracting
any signal from Null-1 control cells treated with the same stimulants (data not shown). Data points represent the values for three
replicates from a representative experiment with median values indicated by the horizontal bar.
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flammatory cytokine secretion into culture supernatants, reiterating the possible im-
pact of vaccine attenuation on cellular activation (Fig. 12B).
These in vitro results with adult PBMC confirm that mycobacterial exposure also
induces myeloid cell activation in human cells and recapitulates the differences in the
degree of activation observed in infant macaques between BCG and our auxotroph
FIG 11 In vitro activation of human monocytes/macrophages by strain mc26435 or BCG. The graphs show the
frequencies of CD16-, CD40-, CD80-, or CD86-positive peripheral blood monocytes/macrophages or mDC after a 5-h
in vitro culture of human PBMC with mc26435, BCG, HK-Mtb, or M. smegmatis mc2155. R848 stimulation served as
a positive control. The data for mc26435- and BCG-stimulated samples were compared by exact Mann-Whitney test.
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vaccine strain mc26435. Further, these experiments were normalized for bacterial dose,
suggesting that the in vivo studies using different dose and route immunization
regimens did not artificially bias immune activation readouts.
DISCUSSION
Vaccines to prevent HIV-1 and TB infections are especially needed for vulnerable
infant populations in resource-poor countries where limited access to therapies results
FIG 12 Cytokine induction in human PMBC. (A) Frequencies of IL-12- or TNF--producing myeloid cells
were determined by flow cytometry after a 5-h culture with strain mc26435, BCG, HK-Mtb, or R848. (B)
Change in IL-6, TNF-, IL-12p70, or IFN- in 24-h culture supernatants of mc26435 or BCG-stimulated
human PBMC compared to medium-only cultures. The P values were determined by exact Mann-Whitney
test.
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in high morbidity and mortality rates. Several new TB vaccine candidates are currently
being pursued, many of which take advantage of the potent adjuvant activity of
mycobacteria and the nonspecific activation of innate and adaptive immune cells,
termed “trained immunity,” which can provide bystander protection against other
pathogens (32, 50). These advantages of mycobacterial vaccinations are especially
attractive features for pediatric vaccines that need to stimulate the immature infant
immune system (51).
Trained immunity was originally described in BCG-vaccinated adults and refers to
the persistence of enhanced monocyte function to mycobacterial antigens and heter-
ologous antigens for several months (15). Recently, it was demonstrated that NK cells
and T cells of BCG-vaccinated adults can also mediate heterologous immunity (15, 16,
52). While enhanced monocyte function in BCG-vaccinated human adults was associ-
ated with NOD2-dependent epigenetic changes (15), the mechanisms mediating
trained immunity in NK cells and T cells of BCG-vaccinated adults have not been
defined. Multiple mechanisms contribute to heterologous immunity. In fact, the phe-
nomenon of vaccine-induced heterologous immunity has been known for many years
and is not limited to BCG, but has also been reported for measles vaccine (31, 53). So
far, only live attenuated vaccines have been shown to confer trained immunity (54),
suggesting that persistent antigen expression might be essential for its induction.
Among the current TB vaccine candidates, the MTBVAC (a mutant of M. tuberculosis)
and the recombinant BCG vaccine VPM1002 represent live attenuated vaccines with the
potential to confer “trained immunity,” and both vaccines have already been shown to
exhibit improved safety compared to BCG, while maintaining immunogenicity (55, 56).
Our AMtb vaccine strain mc26435 (ΔpanCD ΔleuCD ΔsecA2) is similar in concept to
MTBVAC and VPM1002, but it undergoes only limited replication in the mammalian
host (8, 57). However, we cannot exclude the possibility that certain bacterial by-
products persisted in vivo and stimulated innate immune responses. The data of the
current study clearly demonstrated that our AMtb vaccines enhanced the functional
responses of monocytes/macrophages and mDC and that these heightened responses
persisted for at least 16 to 18 weeks after a single AMtb immunization at birth. These
results are consistent with a recent study showing that African infants in Guinea-Bissau
had greater responses to various TLR agonists at 4 weeks after BCG vaccination (58).
Consistent with findings in BCG-vaccinated adults (16), we also observed vaccine-
induced activation of CD4 and CD8 T cells and of B cells. Our results in infant
macaques, which mirrored results from the human pediatric study (58), imply that the
phenomenon of mycobacterial-vaccine-induced trained immunity in adults (16) might
also be applicable to infants. However, we have not specifically tested for the induction
of heterologous immunity and limited cell numbers did not allow us to directly test
whether our AMtb vaccines induced epigenetic modifications in myeloid cell popula-
tions similar to those observed in BCG-vaccinated adults (15). Given our narrow
mechanistic understanding of trained immunity in myeloid and other cell populations,
additional research is needed to enhance our understanding of the complex interac-
tions between vaccine components, innate immune cell activation, and adaptive
immune responses. Such knowledge will be essential to design more-effective and safe
vaccine strategies, both for infant and adult populations.
The potent effects of BCG, and similarly AMtb, vaccines likely explain the improved
immune responses to pediatric vaccines administered to previously BCG-immunized
infants (13, 14). Not surprisingly though, the increased functional capacity of myeloid
cell populations was associated with persistent immune activation. In comparison to
control animals, vaccinated infant macaques had increased levels of MCP-1 in plasma
that positively correlated with in vitro TLR responses, suggesting that systemic immune
activation was driven by myeloid cells, which are target cells for mycobacteria present
in live attenuated TB vaccines.
Despite the obvious benefits of improved myeloid function in the context of the
maturing infant immune system, persistent immune activation can afford greater
susceptibility to HIV infection. Thus, in areas of high HIV prevalence, TB vaccine-induced
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immune activation could potentially increase the risk of HIV infection. In fact, it has
been reported that BCG vaccination in South African newborns induced an increase in
CCR5 and in HLA-DR/CD38-expressing CD4 T cells (11, 12), raising the question of
whether BCG-induced CD4 T cell activation might increase the risk of HIV-1 acquisition
in the pediatric population. Further, immune activation in the intestine or other sites of
virus entry has been associated with increased HIV or SIV acquisition in humans and in
nonhuman primates (59–64). This conclusion is supported by our findings that infant
macaques vaccinated with AMtb or BCG vaccines had increased CD4 CCR5 T cells in
blood and in tissues that serve as presumed entry sites for SIV after oral exposure.
Indeed, as in our recent SIV challenge study (9), AMtb- or BCG-vaccinated infants in the
current study on average required fewer oral SIV exposures to become systemically
infected than unvaccinated animals did, and they had a 1.4-fold higher risk of SIV
infection per exposure than naive controls of similar age. The differences in per
challenge probability of infection did not reach statistical significance between naive
controls and AMtb- or BCG-vaccinated infant macaques. To conclusively demonstrate a
1.4-fold increased risk of SIV infection would require 100 animals per group to achieve
80% power assuming a 25% per challenge probability of SIV infection in naive controls
(http://www.scharp.org/tools/RLDwebCalc/RLD.php), a prohibitive study design for
multiple reasons. Further, each experimental group included one animal that remained
uninfected after 10 exposures, which is not unusual in studies with outbred rhesus
macaques, especially protocols like the present one employing low-dose SIV chal-
lenge regimens (65, 66). Thus, despite the lack of a formally demonstrated statistically
significant difference in acquisition rates between vaccinees and controls, the facts that
(i) both AMtb- and BCG vaccine-primed infants needed fewer SIV exposures to become
infected, (ii) this challenge outcome was observed regardless of vaccine boost, admin-
istration route, or known genetic susceptibility factors for SIV, and (iii) compelling
statistically significant differences in viremia and in immune activation, the trend
toward enhanced SIV acquisition in vaccinated infant macaques may have high bio-
logical significance for human infants who receive the BCG vaccine at birth and are at
risk for HIV acquisition from breast-feeding.
The importance of vaccine-induced immune activation in relation to HIV infection
risk was brought to the forefront by the unexpected results of the STEP HIV vaccine trial
(35). Since then, there have been numerous investigations of the mechanisms respon-
sible for increasing HIV susceptibility in STEP vaccine recipients. Some studies have
suggested that vaccination with the adenovirus 5 (Ad5) vector activated Ad5-specific
memory T cells, increasing the number of target cells for HIV (63, 67–69). However,
others have not been able to confirm these results (70, 71). Two recent nonhuman
primate studies also suggested that the outcome of SIV challenge is associated with
immune activation at the time of challenge. One study showed that PBMC IFN-
enzyme-linked immunosorbent spot assay (ELISPOT) responses inversely correlated
with the number of SIV exposures needed to establish infection in adult macaques (72).
Another study comparing various vaccine modalities showed that regardless of the
vaccine strategy, the number of activated CD4 T cells in the rectal mucosa predicted
early viremia and risk for rectal SIV infection (73). Both studies established a link
between immune activation at the time of challenge and SIV exposure risk, although a
statistically significant difference in challenge outcome between the groups was not
demonstrated (72, 73). Similarly, in a recent low-dose rectal SIV infection study, animals
with higher numbers of Ki67-positive CD4 T cells in the colorectal mucosa required
fewer SIV exposures to become infected (74). These results are particularly reminiscent
of our findings, namely, increased activated CD4 T cells at SIV entry sites and SIV
infection after fewer exposures in vaccinated infants.
Recent in vitro studies provide further evidence that exposure of human CD4 T
cells to M. tuberculosis complex strains including M. bovis BCG or M. tuberculosis H37Rv
derivatives can enhance HIV infection. In the latter study, increased susceptibility was
not associated with increased HIV coreceptor expression, but rather with a TLR2-
dependent mechanism (75). Although we could confirm that mc26435 signals through
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TLR2, it was beyond the scope of our study to test whether AMtb or BCG vaccination
in infant macaques altered TLR2 expression or TLR2 signaling in CD4 T cells. We are
planning to explore this mechanism in future studies because TLR2-dependent mech-
anisms have been implicated in enhanced HIV infectivity (76, 77). The latter study also
showed that exposure of human CD4 T cells to nonpathogenic M. smegmatis mc2155
did not result in increased HIV susceptibility (75). Thus, the identification of the specific
mycobacterial components that are responsible for immune activation could lead to
the design of safer pediatric TB vaccines that do not contain these mycobacterial
components (78). Alternatively, genetic factors known to influence TB pathogenesis,
such as single nucleotide polymorphisms in CCL2 (chemokine [C-C motif] ligand 2) (79),
TLR (80), or cytokine genes (81), could play a role. These are important questions, but
they were beyond the scope of the current study that was focused on risk factors for
oral SIV acquisition. It is noteworthy that we observed differences between AMtb and
BCG vaccine-induced immune activation in the in vivo studies and could confirm these
differences in myeloid cell activation in human PBMC. Mycobacterial strain-specific
differences in response magnitudes suggest that the attenuation of the mycobacterial
vaccine strains might influence host immune responses, HIV/SIV susceptibility, and
disease outcome.
Combined, the data from human studies, adult macaque studies, and the infant
macaque studies here, strongly suggest the need to conclusively determine the risk of
HIV infection in human infants that are vaccinated with BCG or novel TB vaccine
candidates. In areas with a high incidence of TB, even a small increase in the rate of HIV
acquisition would have a major impact on pediatric HIV infections. Importantly, a
recently published study reported that higher frequencies of activated CD4 T cells in
BCG-vaccinated human infants from the MVA85A TB vaccine trial had an increased risk
for TB disease (82). This is the first report that CD4 T cell activation is associated not
only with higher HIV infection risk but also with predisposition to TB disease. Consid-
ering the high susceptibility of neonates and infants in many resource-poor countries
to both HIV and TB, our data reiterate the need to include pediatric populations in
clinical trials testing novel TB vaccines and to incorporate immune activation measure-
ments into vaccine safety assessments. Several of our analyses imply that vaccine-
induced immune activation was less pronounced in infants vaccinated with the auxo-
troph AMtb vaccine than in those vaccinated with BCG. Therefore, an important goal for
future pediatric TB vaccine development should include the design of AMtb or BCG
vaccine strains with reduced nonspecific immune activation to achieve a balance
between potent priming of innate immune responses to induce long-lasting vaccine-
induced memory T and B cell responses while avoiding persistent immune activation
that could enhance susceptibility to HIV. Concern for such risk might be reduced once
(i) new therapeutics, such as long-lasting broadly neutralizing antibodies, become
available as treatment options for breast-feeding infants with HIV-infected mothers, (ii)
more-frequent HIV testing of mother and child during the breast-feeding period
becomes the standard of care, and/or (iii) better adherence of HIV-infected mothers to
antiretroviral drug regimens is achieved.
MATERIALS AND METHODS
Animals. Infant rhesus macaques (Macaca mulatta) were vaginally delivered by colony dams from
the SIV-negative and type D retrovirus-free colony at the California National Primate Research Center
(CNPRC; Davis, CA) and reared in the nursery. Infant macaques of the same experimental group were
cohoused in groups of two or three animals, depending on the group size. We strictly adhered to the
Guide for Care and Use of Laboratory Animals (83) and the standards outlined by the American Association
for Accreditation of Laboratory Animal Care; all animal protocols were reviewed and approved by the
University of California, Davis Institutional Animal Care and Use Committee prior to study initiation.
Animals were randomly assigned to groups and were between 3 and 7 days of age at the first
immunization (week 0 in Fig. 3). For all vaccinations and blood draws, animals were immobilized by 10
mg of ketamine-HCl (Parke-Davis, Morris Plains, NJ) per kg of body weight, injected intramuscularly.
Complete blood counts (CBC) were performed on each peripheral blood sample by the CNPRC Clinical
Laboratory.
Vaccine strains. The vaccine strains described in this study were derived from the human-adapted
M. tuberculosis strain H37Rv as described previously (7, 8, 10). Briefly, the parental H37Rv strain was
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engineered with panCD and leuCD locus deletions to produce a highly attenuated double auxotroph
strain mc26206 unable to synthesize the essential nutrients pantothenate and leucine (57). The mc26206
strain was further attenuated by deletion of the secA2 locus, encoding components of a nonessential
secretion system important for bacterial growth, host immune response restriction, and secretion of
virulence factors, resulting in strain mc26208. Strain mc26208 was further engineered to coexpress
full-length SIVmac239 Gag (mc26435) or Env (mc26439) multimer cassettes that were codon optimized
for expression by mycobacteria. MVA-SIV was kindly provided by B. Moss and P. Earl (NIAID, NIH,
Bethesda, MD) (84–86).
Immunizations. Figure 3 schematically shows the vaccine regimens applied to historical animals
(groups A, B, C1, and D) and animals of the current study. Briefly, naive controls (groups A, C1, and C2)
were immunized at weeks 0, 3, and 6 with sterile phosphate-buffered saline (PBS) (9). Group B (n  8)
and group D animals (n  8) were orally immunized with 109 CFU each of strains mc26435 and mc26439
at birth before receiving systemic boosts intramuscularly (i.m.) (divided over four injection sites) at weeks
3 and 6 with recombinant modified vaccinia virus Ankara expressing SIVmac239 Gag and Pol (MVA vJH4)
and MVA-SIV Env (MVA-SIV; each at 108 infectious units) as described previously (9). The per os (p.o.)
immunizations were done by slowly releasing vaccine with a needleless 1-ml syringe at different sites
within the mouth, including the cheek pouches, the sublingual mucosa, and the top of the tongue.
Therefore, vaccine uptake could occur locally and after swallowing. In the current study, group E animals
(n  6) were primed using the same regimen but received an intradermal (i.d.) boost of a divalent
cocktail of 107 CFU each of strains mc26435 and mc26439 at week 3. We chose to boost group E animals
by the i.d. route because the current TB vaccine BCG is administered by this route. Group F infants (n 
5) were orally immunized at birth with 109 CFU of mc26208 without the SIV expression plasmid. Group
G animals (n  7) received 105 CFU of BCG Danish by the i.d. route (Statens Serum Institute, Denmark,
Copenhagen) as clinically advised for human newborns. Group H infants received a single p.o. immu-
nization of mc26435 at birth. In order to assess the effects of mycobacterial immunizations alone, animals
in groups F, G, and H did not receive booster immunizations.
SIV challenge. As described previously (9), low-dose exposures to virulent SIVmac251 (500 TCID50)
were administered orally under light anesthesia beginning at week 9 to naive controls (group C) and
vaccinated infant macaques (3 or 6 weeks after the last immunization in group D or group E infants,
respectively, and 9 weeks after vaccination of infants in groups F and G). The p.o. SIV exposures were
performed analogously to the p.o. immunizations in volumes of 1 ml. Animals were challenged weekly
until SIV viral RNA levels in plasma indicated persistent infection. We defined persistent infection as 3 or
more consecutive weeks of plasma viremia greater than the highest limit of detection over the course
of the study (65 copies of SIV RNA/ml of plasma). Due to the low-dose nature of the challenge model,
some animals exhibited episodes of very low transient viremia or measurable viral RNA levels at or below
the limit of detection. Animals that failed to become infected after 10 low-dose SIV exposures were right
censored for statistical analysis. All animals were monitored for a minimum of 10 weeks after SIV infection
and were euthanized before they met clinical criteria established for retrovirus-infected animals (87).
Sample collection and processing. EDTA-anticoagulated blood samples were longitudinally col-
lected prior to all interventions throughout the study period. Infant blood sample volumes were
based on infant weight and ranged from 0.5 to 3.5 ml per bleed over the course of the study. Plasma was
isolated from whole blood by centrifugation and stored in multiple small aliquots at 80°C. At
euthanasia, bronchoalveolar lavage (BAL) fluid samples were collected. Recovered BAL fluid samples
were centrifuged to pellet cells which were resuspended in complete RPMI 1640 medium for flow
cytometric analysis, while supernatant was aliquoted and stored separately at 80°C.
At euthanasia, multiple tissues, including tonsil, lymph nodes (LN) (axillary, mesenteric, retropharyn-
geal, and submandibular), spleen, and intestinal tissues (colon and ileum) were also collected. Tissues
were divided into multiple aliquots and (i) formalin fixed/paraffin embedded, (ii) preserved in RNAlater,
or (iii) placed in complete media for fresh tissue analysis as previously described (10, 65). Single-cell
suspensions for cellular immunity assays were prepared using density gradient centrifugation (whole
blood, spleen), gentle homogenization (lymph nodes, tonsil), or collagenase digestion and gradient
centrifugation (mucosal tissues) as described previously (10, 65). For the analysis of archived samples,
cryopreserved peripheral blood mononuclear cell (PBMC) and tissue cell suspensions from historical
animals (9, 10) were quickly thawed at 37°C, immediately washed two times in 37°C serum-free AIM V
medium (Thermo Fisher Scientific) supplemented only with antibiotics and allowed to rest overnight at
37°C in 5% CO2. The cells were washed the next day prior to staining for flow cytometric analysis.
SIV RNA analysis. Longitudinal plasma samples were used for virological analysis by reverse
transcription-PCR (RT-PCR) for SIV RNA essentially as described but with manual RNA extraction for
samples with limited volumes (88). Note that limits of detection depended on input plasma volume and
ranged from 3 to 65 copies/ml, with a mean of 26 and median of 30. Samples showing transient low
viremia followed by SIV RNA-negative time points were retested to confirm the initial PCR results. Data
are reported as the number of SIV RNA copy equivalents per milliliter of plasma.
MHC class I allelic typing. DNA from cryopreserved splenic cell suspensions was typed for common
major histocompatibility complex (MHC) class I variants Mamu-A*01, -A*02, -A*08, -A*11, -B*01, -B*03,
-B*04, -B*08, -B*17, and -B*29 chosen for their possible roles in restricting SIV infection and/or control of
viremia (Table 1). Animals that did not express any of the assayed allelic variants were defined as
“negative” (Table 1). Genotyping was completed by the MHC Genotyping Service at the University of
Miami Miller School of Medicine using previously reported methods (41, 42, 89–92).
TRIM5 genotyping. The TRIM5 genotype of macaques was determined by sequence analysis of
the C-terminal B30.2/SPRY domain of the TRIM5 gene as described previously (9). The genotypes of
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TRIM5TFP, TRIM5Q, and TRIM5CypA were identified, and animals were classified as resistant, intermediate, or
sensitive as described previously (39, 40).
Flow cytometry. The expression of phenotypic markers, activation markers, and cytokines was
evaluated using flow cytometry for T cells, B cells, and monocytes/macrophages in single-cell suspen-
sions from blood and tissues. The cells were stained using rhesus macaque cross-reactive antibodies for
phenotype (CD3 [clone SP34-2], CD4 [clone L200], CD8 [clone RP4-T8], CD11c [clone S-HCL-3], CD14
[clone M5E2], CD16 [clone 3G8], CD20 [clone 2H7], and HLA-DR [clone L243]), activation (CCR5 [clone
3A9], CD69 [clone FN50], Ki-67 [clone B56], PD-1 [clone eBioJ105], CD40 [clone 5C3], CD80 [clone L307.4],
and CD86 [clone FUN-1]), and cytokine expression (IL-2 [clone MQ1-17H12], TNF- [clone mab11], IFN-
[clone B27], IL-17 [clone eBio64CAP17], and IL-12 [clone C8.6]) markers alongside a fixable LIVE/DEAD
discriminator (Invitrogen). All antibodies were obtained from BD Biosciences, except for PD-1 and IL-17
(eBioscience). The cells were fixed in 1% paraformaldehyde, transferred to PBS, and stored in the dark at
4°C until flow cytometric analysis, which was performed within 24 h. All staining panels were evaluated
using fluorescence-minus-one (FMO) controls. Per each sample, 300,000 live, singlet events were
acquired on an LSRII instrument. Using FlowJo software (TreeStar, Ashland, OR), cell populations from all
staining panels were analyzed by first removing cell debris, multiplet events, and nonviable cells.
Monocyte populations were phenotypically defined as CD3 CD20 CD14 HLA-DR, and myeloid
dendritic cells were defined as CD3 CD14 CD20 CD11c HLA-DR. Within the lymphocyte gate, T
cells were defined as CD3 cells and further categorized by expression of either CD4 or CD8 markers to
identify classical T cell subsets. B cells were defined within the lymphocyte gate as CD3 CD14 CD20.
Intracellular cytokine responses were reported based on Boolean gating strategies and after subtraction
of background responses from unstimulated controls.
In vitro activation of rhesus macaque blood and tissue myeloid cell populations. Mononuclear
cell suspensions were cultured in complete RPMI 1640 medium in 5-ml fluorescence-activated cell
sorting (FACS) tubes with R848 (1 g/ml; InvivoGen) and incubated for 5 h at 37°C/5% CO2. At 1 h,
brefeldin A (3 g/ml) was added. Unstimulated cells were used in parallel as controls, and any
background signal was subtracted from treated cell responses accordingly. Cells were analyzed for
activation markers and cytokine production by flow cytometry as described above.
ELISA/Luminex. Plasma samples (week 9) were thawed on ice and centrifuged to pellet and remove
cellular debris. Plasma samples were then analyzed in duplicate using the nonhuman primate Procar-
taPlex 37-plex cytokine/chemokine/growth factor panel (eBioscience) according to the manufacturer’s
protocol. The assay quantified brain-derived neurotrophic factor (BDNF), B lymphocyte chemoattrac-
tant (BLC), eotaxin, fibroblast growth factor 2 (FGF-2), granulocyte colony-stimulating factor (G-CSF),
granulocyte-macrophage colony-stimulating factor (GM-CSF), alpha interferon (IFN-), IFN-, interleukin
1 (IL-1), IL-10, IL-12p70, IL-13, IL-15, IL-17A, IL-18, IL-1 receptor antagonist (IL-1RA), IL-2, IL-23, IL-4, IL-5,
IL-6, IL-7, IL-8, interferon-inducible protein of 10 kDa (IP-10), interferon-inducible T cell alpha chemoat-
tractant (I-TAC), macrophage chemoattractant 1 (MCP-1), monokine induced by gamma interferon (MIG),
macrophage inflammatory protein 1 (MIP-1), MIP-1, nerve growth factor  (NGF-), platelet-derived
growth factor with two B chains (PDGF-BB), soluble CD40 ligand (sCD40L), stem cell factor (SCF), stromal
cell-derived factor 1 (SDF-1), tumor necrosis factor alpha (TNF-), vascular endothelial growth factor
A (VEGF-A), and VEGF-D. Plasma levels of sCD14 and sCD163 were measured at birth, on week 9, and at
euthanasia by enzyme-linked immunosorbent assay (ELISA) (R&D Systems), according to the manufac-
turer’s protocol.
Immunohistochemistry. Immunohistochemistry for myeloperoxidase, Ki-67, and claudin-3, and
quantitative image analysis was performed as previously described (93–96).
M. tuberculosis isolation. Multiple tissues (lung, bronchial LN, axillary LN, spleen) were snap-frozen
and stored at 80°C until shipment to the USDA ARS National Animal Disease Center (Ames, IA) to
recover viable mycobacteria using three different culture methods: (i) the fast indicator tube test (MGIT),
(ii) Middlebrook 7H12 medium (BacTec), and (iii) solid culture media to determine CFU. Because vaccine
strains are auxotrophic, pantothenate- and leucine-supplemented media were used to ensure maximal
bacterial recovery. A tissue was considered positive if one of three culture methods yielded mycobac-
terial growth. M. tuberculosis positive-control samples were run in parallel for quality assurance, and the
analysis was performed in a blind manner.
HEK TLR reporter cell assay. 293HEK-derived cell lines with an NF-B-inducible secreted embryonic
alkaline phosphatase (SEAP) reporter engineered to individually express human Toll-like receptor 2
(TLR2), TLR4, or TLR8 were purchased from InvivoGen (San Diego, CA). The Null-1 parental cell line was
used as a control. According to the manufacturer’s instructions, the cell lines were passaged twice in
growth media (Dulbecco modified Eagle medium [DMEM] supplemented with 10% fetal bovine serum
[FBS], 4.5 g/liter glucose, 2 mM L-glutamine, 50 U/ml penicillin, 50 g/ml streptomycin [all from Gibco],
and 100 g/ml normocin [InvivoGen]) before the cell lines were expanded under antibiotic selection for
plasmid maintenance (1 HEK-Blue Selection for TLR2 and TLR4 cell lines and 30 g/ml blasticidin and
100 g/ml zeocin for the TLR8 cell line; all InvivoGen). Cell lines were used for reporter detection
experiments between passages 8 and 10, at which time the cells were resuspended in HEK-Blue
detection media (InvivoGen) and plated at 50,000 cells/well on 96-well plates with a flat bottom. Human
embryonic kidney (HEK) TLR2, TLR4, and TLR8 cells were stimulated in triplicate with previously titrated
(i) recombinant human TNF- (1 g/ml), (ii) heat-killed M. tuberculosis (HK-Mtb; 100 g/ml), (iii) ultrapure
lipopolysaccharide from Escherichia coli K-12 (LPS-EK) (1 g/ml), (iv) R848 (5 g/ml) (items 1 to iv all from
InvivoGen), (v) AMtb-SIV vaccine strain mc26435 (multiplicity of infection [MOI] of 5), (vi) M. bovis bacillus
Calmette-Guérin (MOI of 5), (vii) M. smegmatis mc2155 (MOI of 5), or (viii) sterile molecular-grade water
(Gibco). The plates were incubated at 37°C and 5% CO2 and monitored longitudinally for 24 h.
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TLR-specific signaling was quantified by measuring the colorimetric change induced by HEK-Blue
detection medium substrate hydrolysis by SEAP secreted into supernatant by spectrophotometry at 650
nm. The reported values are the colorimetric readings after 15 h of stimulation minus background from
Null-1 control cell wells and are representative of longitudinal results through 24 h.
Human peripheral blood. The use of human peripheral donor blood for research use was approved
by the University of North Carolina at Chapel Hill Institutional Review Board. Blood samples were
collected from deidentified healthy adult donors following informed written consent and preserved in
EDTA before use within 24 h of collection. The BCG immunization status and purified protein derivative
(PPD) reactivity of the blood donors was not disclosed. Mononuclear cells were purified from peripheral
blood (PBMC) using density gradient centrifugation over lymphocyte separation medium (MP Biomed-
ical). The cells were resuspended in RPMI 1640 medium (Cellgro) supplemented with 10% heat-
inactivated FBS (Gibco) and L-glutamine–penicillin–streptomycin antibiotic cocktail (Sigma) and were
used immediately for functional assays.
In vitro human myeloid cell activation. PBMC (2  106 cells/ml) from eight healthy human adult
donors were cultured in complete RPMI 1640 medium in 5-ml FACS tubes with (i) strain mc26435 (MOI
of 5), (ii) BCG (MOI of 5), (iii) HK-Mtb (5 g/ml; HKMT [InvivoGen]), or (iv) R848 (1 g/ml; InvivoGen) and
incubated for 5 h at 37°C and 5% CO2, with brefeldin A being added for the last 4 h of culture.
Unstimulated cells were used in parallel as controls, and any background signal was subtracted from
treated cell responses accordingly. Cells were analyzed for activation markers and cytokine production
by flow cytometry as described above.
In vitro cytokine production by human PBMC. Human PBMC (1  106) from eight healthy adult
donors were incubated in 1 ml of complete RPMI 1640 medium in 12-well plates with strain mc26435
(MOI of 5), BCG (MOI of 5), or sterile PBS. Culture supernatants were harvested after 18 h, centrifuged,
fractioned into small aliquots, and stored at 80°C until ELISA analysis. Each assay was titrated to
determine optimal dilutions. Human ELISAs targeting TNF- and IL-12p70 were purchased from eBio-
science, and culture supernatants were assayed at a dilution of 1:10 and undiluted, respectively. Human
high-sensitivity IL-6 and IFN- ELISAs were purchased from R&D Systems and assayed at 1:500 and 1:1
dilutions, respectively. Culture supernatants plus eight dilution standards were assayed in triplicate wells.
Reported concentrations have been adjusted first for reference wavelength values and background
absorbance from cell-free media before replicates were averaged and multiplied by the relative dilution
factor, when applicable.
Statistical analysis. Data were analyzed using GraphPad Prism and InStat software (version 6;
GraphPad Software, Inc., La Jolla, CA) and SAS version 9.3 (Cary, NC). The probabilities of infection per SIV
exposure for naive controls or vaccinated animals were estimated in each group by the number of
infected animals divided by the total number of exposures until infection or censoring and were used to
estimate the relative risk of infection per exposure. The risk of infection per cumulative number of
exposures was estimated using the Kaplan-Meier method and compared between vaccine groups with
an exact log rank test. Nonparametric, exact Mann-Whitney tests were used to compare distributions of
variables not subject to censoring between two groups. We applied individual exact Mann-Whitney tests
because each pairwise comparison was of interest and because the group sizes were small. The exact
Wilcoxon signed-rank test was used for within group comparisons of the same variable at two time
points. Correlations between two continuous variables were evaluated by Spearman rank test. All
statistical tests were two-sided, and P values of0.05 were considered statistically significant. Figures do
not show P values that did not reach statistical significance, and no adjustment was applied for multiple
testing.
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